Regeneron Pharmaceuticals

REGN

Market cap $79.9B

Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.

Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model

Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.

Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.